-transparent.png){kind=logo}
Thapsigargin, a protein kinase C-independent tumor promoter, can negatively regulate the epidermal growth factor (EGF) receptor through inhibition of high affinity EGF binding and EGF-stimulated tyrosine kinase activity. In contrast to activators of protein kinase C, thapsigargin does not induce significant phosphorylation of threonine 654. However, thapsigargin does stimulate phosphorylation of the EGF receptor at other serine and threonine residues. We now identify threonine 669 as the major site of phosphorylation on the EGF receptor resulting from thapsigargin treatment. These results raise the possibility that phosphorylation of threonine 669 may mediate changes in the binding and kinase state of the EGF receptor.
K Takishima, and
B Friedman, and
H Fujiki, and
M R Rosner
June 1989,
The Journal of biological chemistry,
K Takishima, and
B Friedman, and
H Fujiki, and
M R Rosner
August 1991,
The Journal of biological chemistry,
K Takishima, and
B Friedman, and
H Fujiki, and
M R Rosner
October 1998,
Molecular and cellular biochemistry,
K Takishima, and
B Friedman, and
H Fujiki, and
M R Rosner
September 1994,
The Biochemical journal,
K Takishima, and
B Friedman, and
H Fujiki, and
M R Rosner
October 1995,
Biochemical and biophysical research communications,
K Takishima, and
B Friedman, and
H Fujiki, and
M R Rosner
June 1985,
Proceedings of the National Academy of Sciences of the United States of America,
K Takishima, and
B Friedman, and
H Fujiki, and
M R Rosner
October 2019,
Biochemical and biophysical research communications,
K Takishima, and
B Friedman, and
H Fujiki, and
M R Rosner
February 1984,
The Journal of biological chemistry,
K Takishima, and
B Friedman, and
H Fujiki, and
M R Rosner
September 2009,
Cancer biology & therapy,
K Takishima, and
B Friedman, and
H Fujiki, and
M R Rosner
September 1988,
The Journal of biological chemistry,
